Mumbai-based Innovcare Lifesciences operates across the Indian market and focuses on marketing, distributing, and selling pharmaceutical products, nutraceuticals, and cosmeceuticals.
The acquisition is expected to strengthen Sun Pharma’s global footprint while broadening its presence in women’s health, biosimilars, and established medicines.
Once fully operational, the manufacturing plant is expected to create direct employment opportunities for more than 500 people.
The U.S. Food and Drug Administration (FDA) recently approves an updated label for UNLOXCYT based on long-term follow-up data from the pivotal CK-301-101 clinical trial.